|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||197.57 - 203.05|
|52 Week Range||187.16 - 468.55|
|Beta (5Y Monthly)||0.44|
|PE Ratio (TTM)||19.51|
|Earnings Date||Jul 20, 2022 - Jul 25, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||242.00|
Subscribe to Yahoo Finance Plus to view Fair Value for BIIB
If you want to know who really controls Biogen Inc. ( NASDAQ:BIIB ), then you'll have to look at the makeup of its...
When the pandemic hit, in-person lessons at the Community Lab paused. That’s when Biogen-Lemelson-MIT Program Biotech in Action launched, providing online science and lab classes. Going virtual all...
Biogen and development partner Eisai are looking to get their next Alzheimer's drug to market using the FDA's accelerated approval pathway.